Berenberg analyst Kerry Holford lowered the firm’s price target on Novo Nordisk (NVO) to DKK 610 from DKK 725 and keeps a Hold rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Merck (NYSE:MRK) Becomes Latest Big Pharma Stock to Tap China with $2B Heart Disease Drug Rights Deal
- Germany’s SAP (SAP) Is Now Europe’s Largest Publicly Traded Company
- Strategic Positioning and Growth Potential: Evan Seigerman’s Buy Rating on Novo Nordisk
- Novo Nordisk Stock (NVO) Plunges as It Shells Out $2 Billion on Chinese Weight Drug
- Novo Nordisk expands Wegovy $499-per-month offering